Publications
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective studyInsights
Explore the expertise, insights, and perspectives from OPEN Health that help transform complexity into clarity across today’s healthcare landscape.